These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33416171)

  • 21. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
    Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
    Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SREBP2 contributes to cisplatin resistance in ovarian cancer cells.
    Zheng L; Li L; Lu Y; Jiang F; Yang XA
    Exp Biol Med (Maywood); 2018 Apr; 243(7):655-662. PubMed ID: 29466876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
    Bratasz A; Selvendiran K; Wasowicz T; Bobko A; Khramtsov VV; Ignarro LJ; Kuppusamy P
    J Transl Med; 2008 Feb; 6():9. PubMed ID: 18302761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
    Qin S; Li Y; Cao X; Du J; Huang X
    Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteopontin Splicing Isoforms Contribute to Endometriotic Proliferation, Migration, and Epithelial-Mesenchymal Transition in Endometrial Epithelial Cells.
    Ho NT; Lin SW; Lee YR; Tzeng CR; Kao SH
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chloroquine reverses chemoresistance via upregulation of p21
    Hwang JR; Kim WY; Cho YJ; Ryu JY; Choi JJ; Jeong SY; Kim MS; Kim JH; Paik ES; Lee YY; Han HD; Lee JW
    Cell Death Dis; 2020 Dec; 11(12):1034. PubMed ID: 33277461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platinum sensitivity of ovarian cancer cells does not influence their ability to induce M2-type macrophage polarization.
    Mlynska A; Povilaityte E; Zemleckaite I; Zilionyte K; Strioga M; Krasko J; Dobrovolskiene N; Peng MW; Intaite B; Pasukoniene V
    Am J Reprod Immunol; 2018 Sep; 80(3):e12996. PubMed ID: 29904979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Selected Signaling Proteins on SNAIL 1 and SNAIL 2 Expression in Ovarian Cancer Cell Lines in Relation to Cells' Cisplatin Resistance and EMT Markers Level.
    Kielbik M; Szulc-Kielbik I; Klink M
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33478150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of MUTYH contributes to cisplatin‑resistance of esophageal squamous cell carcinoma cells by promoting Twist‑mediated EMT.
    Guo Y; Jia Y; Wang S; Liu N; Gao D; Zhang L; Lin Z; Wang S; Kong F; Peng C; Liu Y
    Oncol Rep; 2019 Dec; 42(6):2716-2727. PubMed ID: 31578574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780.
    Solár P; Sytkowski AJ
    Cancer Lett; 2011 Oct; 309(1):11-8. PubMed ID: 21676537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SATB1 Knockdown Inhibits Proliferation and Invasion and Decreases Chemoradiation Resistance in Nasopharyngeal Carcinoma Cells by Reversing EMT and Suppressing MMP-9.
    Zhou D; Ye C; Pan Z; Deng Y
    Int J Med Sci; 2021; 18(1):42-52. PubMed ID: 33390772
    [No Abstract]   [Full Text] [Related]  

  • 33. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
    Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
    Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells.
    Guo J; Satoh K; Tabata S; Mori M; Tomita M; Soga T
    BMC Cancer; 2021 Feb; 21(1):174. PubMed ID: 33596851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
    Song K; Li Z; Seth P; Cowan KH; Sinha BK
    Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteopontin-4 and Osteopontin-5 splice variants are expressed in several tumor cell lines.
    Silva GR; Mattos DS; Bastos ACF; Viana BPPB; Brum MCM; Ferreira LB; Gimba ERP
    Mol Biol Rep; 2020 Oct; 47(10):8339-8345. PubMed ID: 33006711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
    Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
    Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
    Xiao F; Li Y; Wan Y; Xue M
    Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma.
    Sullivan J; Blair L; Alnajar A; Aziz T; Ng CY; Chipitsyna G; Gong Q; Witkiewicz A; Weber GF; Denhardt DT; Yeo CJ; Arafat HA
    Surgery; 2009 Aug; 146(2):232-40. PubMed ID: 19628079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.